Berk M

IMPACT Institute, Deakin University, Australia.

8 papers · ORCID

ArticleKetamine

Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS study.

Glozier N, Morris R, Stratton E +21

Europe PMC2026
ArticleMDMA

Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.

Højlund M, Kafali HY, Kırmızı B +33

Europe PMC2025
ArticleKetamine

Lithium Augmentation in Treatment-Resistant Depression: A Qualitative Review of the Literature.

Acero-González A, Guzman Y, Proaños NJ +6

Europe PMC2025
ArticleKetamine

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial: commentary, author response.

Loo C, Alonzo A, Barton D +9

Europe PMC2025
ArticleKetamine

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.

Loo C, Glozier N, Barton D +35

Europe PMC2023
ArticleKetamine

Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.

McIntyre RS, Alsuwaidan M, Baune BT +24

Europe PMC2023
ArticlePsilocybin

Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy.

Dodd S, Norman TR, Eyre HA +4

Europe PMC2023
ArticlePsilocybin

Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.

Perkins D, Sarris J, Rossell S +17

Europe PMC2021